Business Context and Reporting Period
This Form 8-K Current Report, dated November 21, 2024, addresses Scilex Holding Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. The filing details the entry into material definitive agreements to waive events of default triggered by this delay under the company's existing debt instruments.
Key Financial Metrics and Debt Obligations
The filing focuses on the company's debt structure rather than operational revenue or profit metrics, as the Q3 2024 financial statements have not yet been filed.
- Oramed Note: Initial principal of $101.875 million; remaining principal is approximately $37.0 million.
- Tranche B Notes: Initial aggregate principal of $50.0 million; approximately $9.0 million has been converted to common stock, leaving a remaining principal of approximately $41.0 million.
- Total Outstanding Debt: Approximately $78.0 million in principal across the Existing Notes.
- Liquidity: The filing does not provide specific cash balance or liquidity figures.
Material Changes and Agreements
On November 21, 2024, Scilex entered into waivers with its lenders to prevent immediate acceleration of debt due to the late filing of the Q3 10-Q.
- Oramed Waiver: Oramed Pharmaceuticals Inc. waived the default regarding the failure to file the Q3 10-Q by November 14, 2024.
- Tranche B Waivers: Investors (Nomis Bay Ltd, BPY Limited, Oramed, and 3i, LP) waived the default and cross-default provisions related to the Q3 10-Q filing delay.
- New Deadlines: The company agreed to deliver the September 2024 Financial Statements by January 20, 2025.
- Auditor Change: The company committed to engaging a new independent registered public accounting firm from a list provided to Oramed or a firm of similar standing to prepare the delayed financial statements.
Outlook, Risks, and Contingencies
Management faces significant risks regarding compliance and capital structure if the new deadlines are not met.
- Default Risk: Failure to file the Q3 10-Q by January 20, 2025, or engage the new auditor, could trigger an event of default. This would allow lenders to accelerate payment, demand redemption of notes, and impose penalty interest and liquidated damages.
- Nasdaq Compliance: There is no assurance the company will regain compliance with Nasdaq listing rules or the Minimum Bid Price Requirement.
- Financing Risk: The company may lack sufficient funds to repay indebtedness if accelerated, potentially leading to enforcement of security interests or substantial dilution.
- Forward-Looking Statements: The company cautions that actual results may differ materially from projections regarding the timing of the 10-Q filing and auditor engagement.
Investor Verification Checklist
- Verify the engagement of a new independent registered public accounting firm by the Audit Committee.
- Monitor the filing of the Q3 2024 Form 10-Q to ensure it is submitted by the January 20, 2025 deadline.
- Review the company's status regarding Nasdaq listing compliance and the Minimum Bid Price Requirement.
- Assess the company's liquidity position and ability to service approximately $78.0 million in outstanding debt principal.
- Check for any subsequent filings indicating a failure to meet the January 2025 deadline or further defaults.